Groowe Groowe / Newsroom / TVRD
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

TVRD News

Tvardi Therapeutics, Inc. Common Stock

Form 8-K

sec.gov
TVRD

Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update

globenewswire.com
TVRD

Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference

globenewswire.com
TVRD

New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)

globenewswire.com
TVRD

Tvardi Therapeutics to Participate in Upcoming Investor Events

globenewswire.com
TVRD

Form 8-K

sec.gov
TVRD

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

globenewswire.com
TVRD

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

globenewswire.com
TVRD

Form 8-K

sec.gov
TVRD

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

globenewswire.com
TVRD